#China #Suzhou #Innovent #Mazdutide #IBI3030

Showcasing Innovent Biologics' Pioneering Research at the ADA 85th Scientific Sessions

Innovent Biologics, Inc., a leading biopharmaceutical company based in both San Francisco and Suzhou, is poised to showcase groundbreaking research at the American Diabetes Association's (ADA) 85th Scientific Sessions. This prestigious event will highlight several exploratory mechanism-of-action (MoA) analyses of their innovative drug mazdutide and the preclinical study of IBI3030.

Highlights of the Presentation

IBI3030: A Novel Anti-PCSK9 Antibody-Peptide-Conjugate

At this year’s session, Innovent will unveil the IBI3030, an innovative anti-PCSK9 antibody coupled with peptides targeting GLP-1R, GCGR, and GIPR. This groundbreaking therapeutic option intends to significantly influence cardiovascular metabolic risk markers. The findings, detailed in Poster Number 1886-L, will be presented by Dr. Decheng Ren and demonstrate how the multi-target synergy of IBI3030 effectively lowers LDL-C levels while enhancing fat oxidation capabilities within the liver. Over a variety of animal models, including mice and non-human primates, results indicated that IBI3030 markedly reduced LDL-C levels, improved glucose tolerance, and exhibited exemplary safety profiles.

Mazdutide: Dual Agonist with Multifold Benefits

Besides the IBI3030 findings, Innovent will also dive deep into the mazdutide—the fastest-growing GCG/GLP-1 receptor agonist worldwide. Multiple studies will elucidate mazdutide’s profound impact in managing liver fat, fibrosis reduction, and uric acid levels. In Poster 777-P, researchers will demonstrate that mazdutide outperforms semaglutide in controlling liver fat accumulation by activating critical metabolic pathways. The data from Poster 1616-P further establishes mazdutide's efficacy in alleviating metabolic dysfunction and liver fibrosis. Comparatively, this dual agonist showcases substantial superiority in promoting fatty acid oxidation and regulating lipid metabolism compared to single-receptor therapies.

Mazdutide's Multifaceted Mechanism

The benefits of mazdutide, as discussed in various studies including Poster 775-P, illustrate its effectiveness in substantially reducing serum uric acid levels in hyperuricemic rats. By adjusting metabolic processes within liver cells, mazdutide showcases an ability to enhance fat oxidation while inhibiting pathways related to purine metabolism, promising a comprehensive approach to managing obesity and type 2 diabetes. This multifaceted mechanism represents a significant step forward in innovative diabetes treatment strategies.

Future Directions

Dr. Lei Qian from Innovent remarked, “We’re thrilled to present mazdutide's extensive explorations at the ADA conference. This growing body of scientific evidence aims to validate mazdutide’s unique benefits as a next-generation treatment, especially concerning cardiovascular risks and metabolic issues.” Innovent's continued commitment to developing next-generation therapies aims not only to enhance patient outcomes but also to ensure accessibility worldwide. Both IBI3030 and mazdutide are prime examples of Innovent’s mission to create impactful solutions against pressing health challenges.

Clinical Trials and Beyond

Mazdutide is currently undergoing a series of Phase 3 clinical evaluations targeting various patient profiles, including those with obesity and diabetes. Specifically, GLORY-1 and DREAMS-1 trials have shown successful outcomes, with ongoing assessments set to expand our understanding of this drug's long-term effectiveness and safety.

Additionally, upcoming studies will explore applications for adolescents with obesity and potential new indications in metabolic disorders.

Innovent Biologics: Commitment to Quality and Care

Founded in 2011, Innovent is dedicated to delivering high-quality, affordable biopharmaceutical products developed through stringent quality assurance practices. With collaborations with over 30 global healthcare entities, including Eli Lilly, Innovent aims to continue its trajectory towards innovation in pharmaceuticals.

For real-time updates and more information, visit Innovent’s website at www.innoventbio.com, and follow their progress on social media platforms. The upcoming ADA conference session stands as a testament to their commitment to enhance healthcare through science and innovation.